Log in to your Inderes Free account to see all free content on this page.
Novakand Pharma
0.16 SEK
+2.76 %
Less than 1K followers
NOVKAN
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+2.76 %
-15.64 %
-43.64 %
-91.36 %
-85.70 %
-86.11 %
-92.48 %
-98.88 %
-99.56 %
Novakand Pharma is a pharmaceutical company. The company develops drugs that counteract damage caused by acute and chronic inflammation. The products are mainly developed to counteract hyperinflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe viral infections. Novakand Pharma is planning two clinical phase II studies, in COVID-19 and in heart patients. The company conducts research and development at Karolinska Institutet Science Park in Stockholm.
Read moreMarket cap
18.95M SEK
Turnover
284.28K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20.2.
2026
Annual report '25
22.5.
2026
Interim report Q1'26
25.5.
2026
General meeting '26
All
Webcasts
Press releases
ShowingAll content types
Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851
Novakand Pharma provides an update on the ongoing reverse take over process
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio